The invention provides novel treatments (methods, uses and compositions) for treating inflammatory disease based on administering to the subject a combination of at least three agents targeting multiple death-receptor inducing systems, the combination comprising: (1) a first agent that neutralises the receptor TNFR1 or a ligand thereof； and (2) a second agent that neutralises either of: (2a) TRAIL-R, or a ligand thereof； or (2b) CD95, or a ligand thereof； and: (3) a third agent that neutralises any of: (3a) TLR3, or TLR4, or a ligand of either； or (3b) a further, different, receptor which is a TNF Receptor superfamily member shown in Table 1, or a ligand thereof； (3c) Caspase； (3d) RIPK1.
